'Show me the money!' MDA greenlights grants

July 13, 2009

TUCSON, Ariz., July 13, 2009--At a time when federal and private funds for biomedical research have become scarce, the Muscular Dystrophy Association reasserts its leadership in the fight against muscle diseases by announcing grants to innovative research projects throughout America and in Canada.

"Federal support for the type of work we do has just about dried up, especially in the current economic climate. Simply put, without the support of MDA, this line of investigation could not be pursued by our lab," said Eric Schon, researcher at Columbia University Medical Center in New York.

MDA has committed over $2 billion to fund medical and scientific research, as well as clinical and client services, in its 55-year history.

"These new research grants, just announced at the July MDA Board of Directors meeting, support research to be conducted from 2009 through 2011, totaling almost $5 million. MDA committed approximately $43million to new and ongoing research in 2008," said MDA Chairman of the Board R. Rodney Howell.

There are no cures yet for most muscle diseases, but the research MDA has funded has created the basis for progressive treatments of muscular dystrophy, amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, and spinal muscular atrophy. It also served as the basis for a lifesaving therapy developed by Genzyme for a metabolic muscle disease called Pompe disease.

At Columbia University, Schon has been awarded a three-year $400,000 grant to continue research into diseases of the mitochondria caused by genetic mutations. Mitochondria are the powerhouse of the cell and, when they fail, can cause muscle weakness and pain, diabetes, blindness and heart disease, along with other debilitating and/or fatal conditions. Schon's research may provide the key for treating many muscle diseases.

MDA has awarded a three-year, $900,000 award to Jerry Mendell at Nationwide Children's Hospital in Columbus, Ohio for a study to combat heart disease in muscular dystrophy.

While advances in treatment of the devastating Duchenne muscular dystrophy (DMD) have prolonged boys' lives, physicians are seeing more heart disease develop in young men living with the disease.

"The longer patients with DMD live, the greater the risk of cardiac complications. In this study, we hope to improve cardiac care by establishing the best medication regimen and to look at the best time to start treatment to protect the patient from heart failure," Mendell said.

He added, "It is clear that without the support of MDA this study and others like it could not be done. MDA is devoted to the treatment of Duchenne and the progress that has been made to this date is the result of the MDA commitment."

At the Ottawa Hospital Research Institute, in Ottawa, Ontario, Associate Scientific Director Rashmi Kothary will be able to continue his research seeking answers to the biological processes that cause SMA. MDA is awarding Kothary $300,000 for three years.

Kothary is also affiliated with the University of Ottawa and like so many researchers, he is aware of and affected by the cutback in research funding. "The financial commitment from MDA is critical for the continued research in this area within my laboratory. It will contribute to the training of highly qualified personnel and trainees who will be the future scientists to tackle neuromuscular disease questions."

In San Diego, Hristelina Ilieva of the Ludwig Institute for Cancer Research has been awarded $180,000 over three years to study how defects in the blood-brain barrier contribute to amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. Ilieva hopes to find a way to use genetic therapy to treat hereditary ALS.

"It will also enable my final phase postdoctoral training; thereby providing me what I hope is a major career development opportunity that will form the basis for my own independent career, a career in which I can use both my MD and Ph.D. training in further development of therapies for ALS."

All projects seeking MDA funding are reviewed by leading experts on the Association's Medical Advisory Committee or Scientific Advisory Committee before being presented to the Board for approval.

In all, 272 research applications were submitted to MDA for potential funding. Currently MDA supports 333 research teams around the globe.
-end-
About MDA

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education. The majority of contributions to MDA come from individual donors.

Muscular Dystrophy Association

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.